Neuralink

Neuralink is a privately held American company developing an implanted Brain–computer interface consisting of a coin-sized wireless processor and a set of thin polymer threads carrying electrodes, inserted into cortex by a purpose-built surgical robot. It was founded in 2016 by a group including Elon Musk, who has been its public face and principal funder. The company began implanting the device in humans in January 2024 under an FDA investigational device exemption.

Neuralink's technical contribution is largely in engineering and surgery rather than neuroscience: flexible electrode threads that move with the brain, automated insertion, high channel counts in a sealed wireless package, and a hermetic implant with no percutaneous connector. Its scientific results to date have been communicated mainly through livestreams and company blog posts rather than peer-reviewed publication, which is the most common criticism levelled at it by academic BCI researchers.

§Technology

The N1 implant houses a battery, wireless radio, and signal-processing electronics in a package that sits in a recess milled into the skull, flush with the surrounding bone. From it extend 64 polymer threads bearing 16 electrodes each — 1,024 channels in total — each thread narrower than a human hair and far more compliant than the rigid silicon shanks of a Utah array. The design intent is to reduce the micromotion-driven tissue damage that drives glial encapsulation and signal loss in stiff arrays.

Because the threads are too floppy to insert by hand, the R1 robot uses a needle and optical guidance to place each one individually, steering around surface vasculature. The company described the architecture in a 2019 white paper based on rodent work.¹ Recording, spike detection, and compression happen on the implant; decoded output is sent over Bluetooth to an external device. Users control a cursor by attempting or imagining movement, with the mapping learned by a decoder that is periodically recalibrated — the same basic paradigm of Neural decoding established in academic laboratories two decades earlier.²³

The device is read-only in its current form. It records but does not stimulate, which places it in a different category from the implanted neurotechnologies already in routine clinical use, such as the Cochlear implant and Deep brain stimulation, which write signals in rather than reading them out. Adding a stimulation channel is a stated goal and is required for the visual programme, but the safety profile of chronic cortical stimulation is less well characterized than that of chronic recording.

1. 2016
   Company founded
   Registered in California by Elon Musk and a group of neuroscientists and engineers; publicly reported in early 2017.
2. 2019
   Threads and robot unveiled
   A launch event and accompanying white paper describe polymer electrode threads, robotic insertion, and rodent recordings.
3. 2020
   Pig demonstration
   A livestream shows live neural recordings from an implanted pig, demonstrating a sealed wireless device rather than any new decoding capability.
4. 2021
   Macaque cursor control
   A monkey plays a cursor-based video game using the implant, replicating a capability shown in primate laboratories years earlier.
5. 2023
   Human trial cleared
   The FDA grants an investigational device exemption; the PRIME study opens recruitment for people with quadriplegia.
6. 2024
   First human implants
   The first participant receives the device in January; the company later discloses that many threads retracted from the cortex, and modifies its technique for subsequent surgeries.
7. 2024–2026
   International expansion
   Regulators in Canada, the United Kingdom, and the United Arab Emirates permit studies; the company reports additional participants and a robotic-arm extension study.

§Human trials

The PRIME study enrols adults with quadriplegia from cervical spinal cord injury or amyotrophic lateral sclerosis. The first participant, Noland Arbaugh, received an implant in January 2024 and within weeks was using it to move a cursor, play chess and video games, and operate a computer for long stretches daily.

In the weeks after that surgery a substantial fraction of the threads retracted from the cortex, reducing the number of channels recording usable signal. Neuralink disclosed this in a blog post several months later and reported recovering performance through changes to signal processing and decoding rather than reimplantation.⁴ For the second participant the company said it altered its technique, sculpting the skull surface to reduce the gap under the implant and inserting threads deeper. Thread retraction is a specific instance of the general problem that afflicts every penetrating array: the brain moves, pulses, and reacts to foreign material.

A companion study, CONVOY, extends control from a cursor to an assistive robotic arm, moving the device from computer access toward the broader ambitions of Neuroprosthetics. The company has also said it intends to pursue speech decoding, a capability demonstrated by academic groups using surface and penetrating arrays and covered under Speech neuroprosthesis. A separate programme, Blindsight, aims to restore a crude visual percept by stimulating visual cortex directly; it received an FDA breakthrough device designation in 2024 but had no published human results as of early 2026. Cortical visual prostheses have a long and largely disappointing history, and the resolution limits that constrained earlier efforts — described under Retinal implants and visual prostheses — apply with equal force here.

Company reporting, not trial reporting

Participant counts, performance figures, and adverse-event descriptions for Neuralink's studies have come predominantly from company statements and social media. As of 2026 there is no peer-reviewed clinical publication from the PRIME study, which makes independent assessment of durability, complication rates, and decoder performance impossible.

§Funding and structure

Neuralink is funded by venture capital and by Musk personally. It raised a Series E in 2025 that the company said totalled several hundred million dollars at a valuation in the billions, a figure far above what any BCI company has justified on revenue, since none has an approved product. The capital advantage is real: implant development, robot engineering, animal work, and multi-country regulatory submissions are expensive in a way academic consortia such as BrainGate cannot match.

The founding team has largely dispersed. Several co-founders left within the first few years, and one went on to co-found Precision Neuroscience, which pursues a thin-film surface approach closer to Electrocorticography interfaces than to penetrating threads. Competitors now span the invasiveness spectrum, including Synchron with its endovascular Stentrode, Paradromics with a high-channel penetrating array, and Blackrock Neurotech.

§Reception

Assessments divide along a consistent line. Engineers credit the company with solving practical problems the field had left unsolved: a fully implanted wireless device with no skull-mounted pedestal, an insertion robot that makes hundreds of precise placements, and a manufacturing process for polymer electrode arrays. Those are the bottlenecks between a laboratory demonstration and a product.

Neuroscientists are more sceptical of the framing. The cursor control demonstrated in 2024 was qualitatively similar to results published from academic implants more than a decade earlier, and the product name "Telepathy" describes typing with a decoder, not thought transmission — an overstatement of the kind examined under Brain-to-brain interfaces. Claims that the device will one day enable symbiosis with artificial intelligence, discussed as Human–AI merger, are untested and rest on a bandwidth argument that the low-dimensional structure of cortical activity does not obviously support.

The company has also faced sustained criticism over animal research. Reuters reported in 2022 that federal investigators were examining animal-welfare practices following internal complaints, and a separate inquiry concerned the transport of hardware removed from primate brains.⁵ An advocacy organization filed complaints over primate experiments conducted at a university partner. Neuralink has denied wrongdoing and published its own account of its animal-care programme.

A third strand of criticism concerns data. A device that streams cortical activity to a phone creates a record of neural signals held by a private company, raising the questions taken up under Mental privacy — not because a cursor decoder reads thoughts, but because the underlying recordings support inferences the user never intended to make available.

§Outlook

The questions that will determine whether Neuralink matters are unglamorous. Do threads stay put over five years? What fraction of participants develop infection or require explant? Can a decoder run for weeks without a technician? Does the device work in a home, unsupervised, on a bad day? The company's willingness to run multi-country studies suggests a push toward a pivotal trial, but no implanted BCI from any developer has yet been approved for routine clinical use, and the regulatory path for a permanent cortical implant in a non-fatal condition has no precedent to follow.

A separate question is what happens if the company stops. Implanted devices create obligations that outlast product lines, an issue that the emerging Neurorights frameworks have begun to name but not yet resolved.

§See also

• Brain–computer interface
• Stentrode
• Utah array
• Speech neuroprosthesis
• Neural decoding
• Neuroprosthetics
• Mental privacy
• Synchron

§References